2-(furan-3-yl)acetic acid

Name: 2-(furan-3-yl)acetic acid  (3-furylethanoic acid)

CAS# 123617-80-1


2-(furan-3-yl)acetic acid
2-(furan-3-yl)acetic acid

We have this product in stock.

If you need it somewhere for chemical research, please feel free to contact us.

Email: sales@accelpharmtech.com 

Website: www.accelpharmtech.com


Pharma suffers biggest loss ever of consumer trust

Trust has hit a new low for pharma in Edelman’s annual Trust Barometer survey. The 13-point drop from 51% to 38% in the U.S. was the category’s biggest plummet in the five years the public relations and marketing firm has been tracking sentiment.

Plus, it’s a turnaround in the wrong direction. The big nosedive comes just one year after pharma showed gains of four points in U.S. consumer trust.

While pharmaceutical companies saw the most notable drop, trust fell across the board in all healthcare categories in this year’s U.S. survey. Edelman looks at five healthcare subcategories: pharma, biotech, payers, hospitals and providers, and consumer health.

Biotech saw the next largest drop in trust after pharma, falling by 9 points. At the other end of the scale, hospitals and providers only dropped by 1 and remained the most trusted in healthcare with a score of 70.



Artesunate (AS) is a medication used to treat malaria. Artesunate can be given by injection into a vein, injection into a muscle, or taken by mouth. Artesunate is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.

CAS# 88495-63-0



If you need it somewhere for chemical research, please feel free to contact us.

Email: sales@accelpharmtech.com 

Website: www.accelpharmtech.com

FDA hits CDMO Kolmar Korea with warning letter over manufacturing issues

The FDA issued a warning letter to Korean contract drug manufacturer Kolmar Korea, citing significant GMP issues stemming from an inspection conducted last September.

In a letter posted to the regulatory agency’s website, the FDA said inspectors found that the company failed to investigate out-of-specification results for certain lots of an over-the-counter cream and instead retested and invalidated the OOS results without justification.

Additionally, FDA inspectors said Kolmar Korea didn’t follow its own written procedures for document control, which require quality control unit approval for discarding records. (See more details on fiercepharma)


FDA wants social media giants to help crack down on illegal opioid marketers

The FDA’s latest crackdown targets pharmacies hawking illegal opioids online. The agency issued warning letters this week to nine online pharmacies that run 53 websites selling drugs with suspect monikers like “Roxycodone” and “Tramadol Generic.”

Many of the websites shut down one day later, but at least one—OneStopPharma.org—was still operating Thursday morning.

While legitimate FDA-approved pharma opioid makers had long quit marketing to consumers and even doctors, the illegal online pill-pushing remains rampant. And the FDA is trying to enlist the online platforms that host or display ads from the fly-by-night pharmacies.


Tigecycline is an antibiotic used to treat a number of bacterial infections. It is a glycylcycline that is administered intravenously.

CAS# 220620-09-7



Currently our 500+ kinds inventory products are being on promotion. If you are interested it, please feel free to contact us. Then detailed products will be offered.


If you need it somewhere for chemical research, please contact us:

web: www.accelpharmtech.com

Mail: sales@accelpharmtech.com

Eyeing the most lucrative vaccine market, SutroVax nabs $85M and Moncef Slaoui as chairman

A little more than a year after it raised $64 million to develop a next-gen pneumococcal conjugate vaccine, SutroVax is back with another raise. And this time, it’s tapping an industry veteran to help steer the ship.

SutroVax is targeting a competitive field with some vaccine giants in the mix. Pfizer’s megablockbuster Prevnar 13 currently dominates the pneumococcal vaccine market worldwide, and the drug giant is working on a follow-up designed to protect against 20 strains instead of 13.

“We believe that the vaccine we are advancing could be that dominant vaccine of the future,” Pickering said. Pfizer’s Prevnar 13 brought in $5.6 billion last year, and Pickering noted that very few vaccines reach blockbuster status.

See more details on FiercePharma